✦ LIBER ✦

TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

✍ Scribed by Michael L. Maitland; Kaveeta Vasisht; Mark J. Ratain

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN157 COST-EFFECTIVENESS OF UGT1A1 GENO

✍ M Obradovic; A Mrhar; M Kos 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

Su1843 High Enzyme Activity UGT1A1 or Lo

✍ Dura, Polat; Salomon, Jody; Morsche, Rene te; Roelofs, Hennie; Kristinsson, Jon; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Genotype-directed, dose-finding study of

✍ Taroh Satoh; Takashi Ura; Yasuhide Yamada; Kentaro Yamazaki; Toshimasa Tsujinaka 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Phase II and UGT1A1 genotype study of ir

✍ Jo, J-C; Lee, J-L; Ryu, M-H; Chang, H M; Kim, M; Lee, H J; Kim, H-S; Shin, J-G; 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 357 KB

Uridine Diphosphate Glucuronosyltransfer

✍ O'Dwyer, P. J. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 82 KB

UGT1A1*28 genotype and irinotecan dosage

✍ Kweekel, D M; Gelderblom, H; Van der Straaten, T; Antonini, N F; Punt, C J A; Gu 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 159 KB